DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Röllig C, Serve H, Hüttmann A et al.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol 2015;
16: 1691-1699
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.